Tedizolid, sold under the brand name Sivextro is an oxazolidinone-class antibiotic. Tedizolid phosphate is a phosphate ester prodrug of the active compound tedizolid. It was developed by Cubist Pharmaceuticals, following acquisition of Trius Therapeutics (originator: Dong-A Pharmaceuticals), and is marketed for the treatment of acute bacterial skin and skin structure infections (also known as complicated skin and skin-structure infections (cSSSIs)).[5][medical citation needed]
The most common side effects include nausea (feeling sick), headache, diarrhoea and vomiting.[4] These side effects were generally of mild or moderate severity.[4]
Tedizolid was approved for medical use in the United States in June 2014,[6][7] and for medical use in the European Union in March 2015.[4]
^"Trius grows as lead antibiotic moves forward". 31 Oct 2011.
^"Health Canada New Drug Authorizations: 2015 Highlights". Health Canada. 4 May 2016. Retrieved 7 April 2024.
^Cite error: The named reference Sivextro FDA label was invoked but never defined (see the help page).
^ abcdCite error: The named reference Sivextro EPAR was invoked but never defined (see the help page).
^"Cubist Pharmaceuticals to Acquire Trius Therapeutics". July 2013.
^Cite error: The named reference FDA approval tablets was invoked but never defined (see the help page).
^Cite error: The named reference FDA approval injection was invoked but never defined (see the help page).
Tedizolid, sold under the brand name Sivextro is an oxazolidinone-class antibiotic. Tedizolid phosphate is a phosphate ester prodrug of the active compound...
ranbezolid (RBx 7644), and radezolid (RX-1741). In 2014, the FDA approved tedizolid phosphate, a second-generation oxazolidinone derivative, for acute bacterial...
combination of penicillin and streptomycin therapy was used in the past. Tedizolid, telavancin, dalbavancin, and oritavancin antibiotics are FDA approved...
Clostridium difficile-associated diarrhea, and respiratory syncytial virus. Tedizolid was approved by the US Food and Drug Administration on June 20, 2014....
bacterial pneumonia. The lipoglycopeptide dalbavancin and the oxazolidinone tedizolid has also been approved for use for the treatment of acute bacterial skin...
acute bacterial meningitis in neonates, where meropenem is preferred Tedizolid phosphate is an alternative For use only in patients with HIV receiving...
Global Information
(what is this?) (verify)